Skip to main content
SpringerLink
Log in

Appropriate drug dosages in obese patients

  • Therapy in Practice
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Drug dosage recommendations in obese patients are largely lacking, as data on dosages are generally derived from clinical studies conducted in healthy subjects of average body weight. As morbid obesity (i.e. body mass index ≥ 40 kg/m2) is associated with comorbidities affecting drug pharmacokinetics, relatively few obese subjects are included in clinical studies. To insure optimal drug dosages in obese patients, efficacy and safety trials should provide subgroup analysis of data in patients with varying degrees of obesity. The body-size descriptor used to determine the optimal drug dosage in obese patients should be based on the pharmacological properties of the drug, the clinical context and other factors, and should be clearly specified (including the method of conversion from total body weight to the appropriate body-size descriptor).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856–68.

    Article  PubMed  Google Scholar 

  2. Jacques KA, Erstad BL. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm. 2010;67(22):1948–50.

    Article  PubMed  Google Scholar 

  3. Erstad BL. Improving medication dosing in the obese patient. Clin Drug Investig. 2017;37(1):1–6.

    Article  PubMed  Google Scholar 

  4. Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105(Suppl 1):i16–23.

    Article  CAS  PubMed  Google Scholar 

  5. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119–33.

    Article  PubMed  PubMed Central  Google Scholar 

  6. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6(Suppl 2):51S–209S.

    Google Scholar 

  7. World Health Organisation. Obesity: preventing and managing the global epidemic: report of a WHO consultation (WHO Technical Report Series 894). Geneva: World Health Organization; 2000.

    Google Scholar 

  8. Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017;40(5):189–93.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther. 2014;39(6):584–608.

    Article  CAS  PubMed  Google Scholar 

  10. Xiong Y, Fukada T, Knibbe CAJ, et al. Drug dosing in obese children challenges and evidence-based strategies. Pediatr Clin N Am. 2017;64(6):1417–38.

    Article  Google Scholar 

  11. Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970–6.

    CAS  PubMed  Google Scholar 

  12. Martin JH, Saleem M, Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity: a new use for an old methodology. Br J Clin Pharmacol. 2012;73(5):685–90.

    Article  CAS  PubMed  Google Scholar 

  13. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med. 2004;30(1):18–32.

    Article  PubMed  Google Scholar 

  14. Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet. 2000;39(3):215–31.

    Article  CAS  PubMed  Google Scholar 

  15. Greenwalt M, Griffen D, Wilkerson J. Elimination of emergency department medication errors due to estimated weights. BMJ Qual Improv Rep. 2017; 27; 6(1). https://doi.org/10.1136/bmjquality.u214416.w5476

    Article  PubMed  PubMed Central  Google Scholar 

  16. Institute for Safe Medications Practices (ISMP). 2018-2019 Targeted medication safety best practices for hospitals.: best practice 3. Horsham (PA): ISMP; 2018.

  17. Pan SD, Zhu LL, Chen M, et al. Weight-based dosing in medication use: what should we know? Patient Prefer Adherence. 2016;10:549–60.

    PubMed  PubMed Central  Google Scholar 

  18. Ghobadi C, Johnson TN, Aarabi M, et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients expected variations in clearance. Clin Pharmacokinet. 2011;50(12):809–22.

    Article  CAS  PubMed  Google Scholar 

  19. Painter SD, Ovsyannikova IG, Polanda GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33(36):4422–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Neidich SD, Green WD, Rebeles J, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes (Lond). 2017;41(9):1324–30.

    Article  CAS  PubMed Central  Google Scholar 

  21. Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 2013;65(1):94–100.

    Article  CAS  Google Scholar 

  22. Clinical Excellence Commission. High-risk medicines management policy (document no. PD2015-029). North Sydney (NSW): Ministry of Health, NSW; 2015.

  23. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6(7):438–46.

    Article  PubMed  Google Scholar 

  24. Bertakis LD, Azari R. Obesity and the use of health care services. Obes Res. 2005;13(2):372–9.

    Article  PubMed  Google Scholar 

  25. Pai MP. Anti-infective dosing for obese adult patients: a focus on newer drugs to treat methicillin-resistant Staphylococcus aureus acute bacterial skin and skin structure infections. Clin Ther. 2016;38(9):2032–44.

    Article  PubMed  Google Scholar 

  26. Mahmood I. Prediction of clearance and volume of distribution in the obese from normal weight subjects. Clin Pharmacokinet. 2012;51(8):527–42.

    Article  CAS  PubMed  Google Scholar 

  27. Bhat R, Mazer-Amirshahi M, Sun C, et al. Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED. Am J Emerg Med. 2016;34(12):2423–5.

    Article  PubMed  Google Scholar 

  28. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2012;30(13):1553–61.

    Article  PubMed  Google Scholar 

  29. Shem-Tov N, Labopin M, Moukhtari L, et al. Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncologist. 2015;20(1):50–5.

    Article  CAS  PubMed  Google Scholar 

  30. Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity: results of a meta-analysis. Am Heart J. 2008;155(2):310–5.

    Article  PubMed  Google Scholar 

  31. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118(9):978–80.

    Article  PubMed  Google Scholar 

  32. Kane-Gill SL, Wytiaz NP, Thompson LM, et al. A real-world, multicenter assessment of drugs requiring weight-based calculations in overweight, adult critically ill patients. Sci World J. 2013; 30. https://doi.org/10.1155/2013/909135.

    Article  Google Scholar 

  33. Graves KK, Edholm K, Johnson SA. Use of oral anticoagulants in obese patients. JSM Atheroscler. 2017;2(4):1035.

    Google Scholar 

  34. Hurewitz AN, Khan SU, Groth ML, et al. Dosing of unfractionated heparin in obese patients with venous thromboembolism. J Gen Intern Med. 2011;26(5):487–91.

    Article  PubMed  Google Scholar 

  35. Michota F, Merli G. Anticoagulation in special patient populations: are special dosing considerations required? Cleve Clin J Med. 2005;72(Suppl 1):S37–42.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Otago, 18 Frederick Street, Dunedin, New Zealand

    Sanja Mirkov

  2. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Sanja Mirkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanja Mirkov.

Ethics declarations

Conflict of interest

S. Mirkov and K.A. Lyseng-Williamson declare no relevant conflict of interest.

Funding

The preparation of this review was not supported by any external funding.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mirkov, S., Lyseng-Williamson, K.A. Appropriate drug dosages in obese patients. Drugs Ther Perspect 34, 344–349 (2018). https://doi.org/10.1007/s40267-018-0509-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0509-z

Search

Navigation